Synthesis and antiestrogenic activity of [3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl)ethoxy]-phenyl]methanone, methanesulfonic acid salt.

No abstract is available for this paper.

• Publication year

  1979

• Venue

  Journal of Medicinal Chemistry

• Publication date

  1979-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/JM00194A015PMID 490541
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antiestrogens in the treatment of breast cancer.

  1976cited by this paper
• ANTIOESTROGENS: A REVIEW

  1975cited by this paper
• A radio-ligand binding assay system for estradiol measurement in human plasma.

  1969cited by this paper
• Further clinical experience with clomiphene citrate.

  1968cited by this paper

• Gold-Catalyzed Reactions of o-Alkynylarylaldehydes with Alkenes for the Synthesis of 3,4-Dihydronaphthalene Derivatives.

  2025cites this paper
• Structure-based design and synthesis of conformationally constrained derivatives of methyl-piperidinopyrazole (MPP) with estrogen receptor (ER) antagonist activity.

  2021cites this paper
• Flexible small molecular anti-estrogens with N,N-dialkylated-2,5-diethoxy-4-morpholinoaniline scaffold targets multiple estrogen receptor conformations

  2017cites this paper
• The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators.

  2014cites this paper
• Discovery and Pharmacology of Nonsteroidal Estrogens and Antiestrogens

  2013cites this paper
• Selective Estrogen Receptor Modulators

  2012cites this paper
• Development of Estrogen Antagonists as Pharmaceutical Agents

  2010cites this paper
• Application of the McMurry coupling reaction in the synthesis of tri- and tetra-arylethylene analogues as potential cancer chemotherapeutic agents.

  2009cites this paper
• Preclinical Studies of Raloxifene and Related Compounds

  2009cites this paper
• Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health.

  2008cites this paper
• Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health

  2008influential citation
• Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release.

  2005cites this paper
• Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity.

  2005cites this paper
• Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions.

  2003cites this paper
• Female Sex Hormones, Contraceptives, And Fertility Drugs

  2003cites this paper
• Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.

  2003cites this paper
• Tracing the origins of COX-2 inhibitors' structures.

  2002cites this paper
• Critical Review and Evaluation of the Uterotrophic Bioassay for the Identification of Possible Estrogen Agonists and Antagonists: In Support of the Validation of the OECD Uterotrophic Protocols for the Laboratory Rodent

  2002cites this paper
• Chapter 15. Targeting the estrogen receptor with SERMs

  2001cites this paper
• Similarities and distinctions in the mode of action of different classes of antioestrogens.

  2000cites this paper
• Emerging therapies for the prevention or treatment of postmenopausal osteoporosis.

  1999cites this paper
• Pharmacology of Antiestrogens

  1999cites this paper
• Antiestrogens and Partial Agonists

  1999cites this paper
• Synthesis and relative binding affinity to steroid receptors and antiproliferative activity on MCF-7 cells of 2,3-disubstituted indenes.

  1999cites this paper
• Effects of raloxifene in a guinea pig model for leiomyomas.

  1998cites this paper
• Molecular mechanisms and future uses of antiestrogens.

  1997cites this paper
• Clinical potential of new antiestrogens.

  1997cites this paper
• Evaluation of piperidinoethoxy moiety as an antiestrogenic substituent in non-steroidal anti-estrogens : Fertility regulation

  1997cites this paper
• Synthesis and post-coital contraceptive activity of a new series of substituted 2,3-diaryl-2H-1-benzopyrans

  1997cites this paper
• Heterogeneity of binding sites and bioeffects of raloxifene on the human leukemic cell line FLG 29.1.

  1997cites this paper
• Raloxifene analog (LY117018 HCL) ameliorates cyclosporin A—Induced osteopenia in oophorectomized rats

  1996cites this paper
• Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance.

  1996cites this paper
• Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia.

  1996cites this paper
• Section Review: Oncologic, Endocrine & Metabolic: Drugs in development for the treatment of metabolic bone disease

  1996cites this paper
• Inhibition of estrogen‐stimulated growth of uterine leiomyomas by selective estrogen receptor modulators

  1996cites this paper
• Evidence for bioeffects of LY 139478 on the human pre-osteoclastic cell line FLG 29.1.

  1995cites this paper
• Steroidal affinity labels of the estrogen receptor. 2. 17 alpha-[(Haloacetamido)alkyl]estradiols.

  1995cites this paper
• Recent developments in the chemotherapy of osteoporosis.

  1995cites this paper
• Synthesis and biological activities of thioether derivatives related to the antiestrogens tamoxifen and ICI 164384.

  1995cites this paper
• The effects of raloxifene on tibia histomorphometry in ovariectomized rats.

  1994cites this paper
• Raloxifene preserves bone strength and bone mass in ovariectomized rats.

  1994cites this paper
• Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.

  1994cites this paper
• The biological evaluation of novel antioestrogens for the treatment of breast cancer.

  1993cites this paper
• Nonsteroidal estrogens bearing acyl azide functions: potential electrophilic and photoaffinity labeling agents for the estrogen receptor.

  1992cites this paper
• Antiestrogens. 3. Estrogen receptor affinities and antiproliferative effects in MCF-7 cells of phenolic analogues of trioxifene, [3,4-dihydro-2-(4- methoxyphenyl)-1-naphthalenyl][4-[2-(1-pyrrolidinyl)ethoxy]- phenyl]methanone.

  1992cites this paper
• 2 – ESTROGENS, ANTIESTROGENS, AND OTHER ESTRANE COMPOUNDS

  1992cites this paper
• Endocrine pharmacology of antiestrogens as antitumor agents.

  1990cites this paper
• Structure-activity relationship of antiestrogens. Studies on 2,3-diaryl-1-benzopyrans.

  1990cites this paper
• Structure-activity relationship of antiestrogens. Phenolic analogues of 2,3-diaryl-2H-1-benzopyrans.

  1990cites this paper
• Structure-activity relationship of antiestrogens. Effect of the side chain and its position on the activity of 2,3-diaryl-2H-1-benzopyrans.

  1990cites this paper
• Emerging concepts towards the development of contraceptive agents.

  1989cites this paper
• Structure-activity relationship of antiestrogens: a study using triarylbutenone, benzofuran, and triarylfuran analogues as models for triarylethylenes and triarylpropenones.

  1989cites this paper
• A chemical classification of nonsteroidal antagonists of sex-steroid hormone action.

  1988cites this paper
• Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study.

  1988cites this paper
• Antiestrogens Old and New: The Search for a Non-Toxic Agent with No Estrogenic Properties

  1987cites this paper
• A phase I/II investigation of trioxifene mesylate in advanced breast cancer. Clinical and endocrinologic effects

  1986cites this paper
• Structure-activity relationship of estrogens: receptor affinity and estrogen antagonist activity of certain (E)- and (Z)-1,2,3-triaryl-2-propen-1-ones.

  1985cites this paper
• Biochemical pharmacology of antiestrogen action.

  1984cites this paper
• Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal in

  1984cites this paper
• Antagonism of estrogen action with a new benzothiophene derived antiestrogen.

  1983cites this paper
• Estrogen receptor binding and estrogenic/antiestrogenic effects of two new metabolites of nitromiphene, 2-[p-[2-nitro-1-(4-methoxyphenyl)-2-phenylvinyl]phenoxy]-N-ethylpyrrolidine.

  1983cites this paper
• An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro.

  1983cites this paper
• Importance of the alkylaminoethoxy side-chain for the estrogenic and antiestrogenic actions of tamoxifen and trioxifene in the immature rat uterus.

  1982cites this paper
• Activity of the antioestrogen trioxifene against N-Nitrosomethylurea-induced rat mammary carcinomas.

  1981cites this paper
• Differential interaction of antiestrogens with cytosol estrogen receptors.

  1981cites this paper
• SYNTHESIS AND ANTIESTROGENIC ACITIVITY OF (3,4-DIHYDRO-2-(4-METHOXYPHENYL)-1-NAPHTHALENYL)(4-(2-(1-PYRROLIDINYL)ETHOXY)-PHENYL)METHANONE, METHANESULFONIC ACID SALT

  1980cites this paper
• Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice.

  1980cites this paper
• Selective estrogen receptor modulators (SERMs).

  1970cites this paper